Surveillance of pyrazinamide susceptibility among multidrug-resistant Mycobacterium tuberculosis isolates from Siriraj Hospital, Thailand

BMC Microbiology

Volumn 10, Issue , 2010, Pages

  Jonmalung, Jirarut ^a   Prammananan, Therdsak ^b,d   Leechawengwongs, Manoon ^c,d   Chaiprasert, Angkana ^a,d  

^a MAHIDOL UNIVERSITY   (Thailand)

^b NATIONAL SCIENCE AND TECHNOLOGY DEVELOPMENT AGENCY   (Thailand)

^c Vichaiyut Hospital   (Thailand)

^d Siriraj Foundation   (Thailand)

Author keywords

[No Author keywords available]

Indexed keywords

ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; STREPTOMYCIN; AMIDASE; ANTIINFECTIVE AGENT; PNCA PROTEIN, MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL GROWTH; BACTERIAL MUTATION; BACTERIAL STRAIN; CHILD; CONTROLLED STUDY; CULTURE MEDIUM; DISEASE SURVEILLANCE; DRUG ACTIVITY; FEMALE; HUMAN; MALE; MULTIDRUG RESISTANCE; MULTIDRUG RESISTANT TUBERCULOSIS; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; SCHOOL CHILD; SENSITIVITY AND SPECIFICITY; THAILAND; DRUG EFFECT; ENZYMOLOGY; GENETICS; HEALTH SURVEY; HOSPITAL; ISOLATION AND PURIFICATION; METABOLISM; MICROBIOLOGICAL EXAMINATION; MICROBIOLOGY; MIDDLE AGED; MUTATION; TUBERCULOSIS;

MYCOBACTERIUM TUBERCULOSIS;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMIDOHYDROLASES; ANTI-BACTERIAL AGENTS; ANTITUBERCULAR AGENTS; CHILD; CHILD, PRESCHOOL; DRUG RESISTANCE, MULTIPLE, BACTERIAL; FEMALE; HOSPITALS; HUMANS; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; MUTATION; MYCOBACTERIUM TUBERCULOSIS; POPULATION SURVEILLANCE; PYRAZINAMIDE; THAILAND; TUBERCULOSIS; YOUNG ADULT;

EID: 77955705711     PISSN: 14712180     EISSN: 14712180     Source Type: Journal    
DOI: 10.1186/1471-2180-10-223     Document Type: Article

References (37)

1. WHO Report. Geneva. World Health Organization, 2009
2. Co-infection with human immunodeficiency virus and tuberculosis in Asia. SH Vermund N Yamamoto, Tuberculosis (Edinb) 2007 87 Suppl 1 18 25 10.1016/j.tube.2007.05.008 17631414
3. HIV care and treatment factors associated with improved survival TB treatment in Thailand: an observational study. JK Verma S Nateniyom S Akksilp W Mankatittham C Sirinak W Sattayawuthipong C Burapat W Kittikraisak P Monkongdee KP Cain CD Wells JW Tappero, BMC Infect Dis 2009 9 42 50 10.1186/1471-2334-9-42 19364398
4. Cause of death in HIV-infected persons who have tuberculosis, Thailand. KP Cain T Anekthananon C Burapat S Akksilp W Mankhatitham C Sirinak S Nateniyom W Sattayawuthipong T Tasaneeyapan JK Varma, Emerg Infect Dis 2009 15 258 264 10.3201/eid1502.080942 19193270
5. Characteristics of HIV-infected tuberculosis patients in Thailand. W Mankatittham S Likanonsakul U Thawornwan P Kongsanan W Kittikraisak C Burapat S Akksilp W Sattayawuthipong C Srinak S Nateniyom T Tasaneeyapan JK Verma, Southeast Asian J Trop Med Public Health 2009 40 93 103 19323040
6. Conditions that may affect the results of susceptibility testing of Mycobacterium tuberculosis to pyrazinamide. Y Zhang S Permar Z Sun, J Med Microbiol 2002 51 42 9 11800471
7. The curious characteristics of pyrazinamide: a review. Y Zhang D Mitchison, Int J Tuberc Lung 2003 7 6 21
8. Mode of action of pyrazinamide: disruption of Mycobacterium tuberculosis membrane transport and energetics by pyrazinoic acid. Y Zhang MW Wade A Scorpio H Zhang Z Sun, J Antimicrob Chermother 2003 52 790 795 10.1093/jac/dkg446 (Pubitemid 37407806)
9. Mutation in pncA, a gene encoding pyrazinamidase/nicotinamidase, caused resistance to antituberculous drug, pyrazinamide in tubercle bacillus. A Scorpio Y Zhang, Nature Med 1996 2 662 667 10.1038/nm0696-662 8640557
10. The paradox of pyrazinamide: an update on the molecular mechanisms of pyrazinamide resistance in mycobacteria. P Singh AK Mishra SK Malonia DS Chauhan VD Sharma K Venkatesan VM Katoch, J Commun Dis 2006 38 288 298 17373362
11. Relationship between pyrazinamide resistance, loss of pyrazinamidase activity, and mutations in the pncA locus in multidrug-resistant clinical isolates of Mycobacterium tuberculosis. M Mestdagh PA Fonteyne L Realini R Rossau G Jannes W Mijs KAL de Smet F Portaels VD Eeckhout, Antimicrob Agents Chemother 1999 43 2317 2319 10471589
12. Pyrazinamide resistance among South African multidrug-resistant Mycobacterium tuberculosis isolates. M Mphahlele H Syre H Valvatne R Stavrum T Mannsaker T Mothivhi K Weyer PB Fourie HM Grewal, J Clin Microbiol 2008 46 3459 3464 10.1128/JCM.00973-08 18753350
13. pncA mutations as a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis: spread of a monoresistant strain in Quebec, Canada. SJ Cheng L Thibert T Sanchez L Heifets Y Zhang, Antimicrob Agents Chemother 2000 44 528 532 10.1128/AAC.44.3.528-532.2000 10681313
14. Frequency and implications of pyrazinamide resistance in managing previously treated tuberculosis patients. GE Louw RM Warren PR Donald MB Murray M Bosman PD van Helden DB Young TC Victor, Int J Tuberc Lung Dis 2006 10 802 807 16848344
15. Susceptibility testing of mycobacteria, norcardiae, and other aerobic Actinomycetes: Approved standard NCCLS document M24-A. G Woods EP Desmond GS Hall L Heifets GE Pfyffer, NCCLS 2003
16. Evaluation of the fully automated BACTEC MGIT 960 system for testing susceptibility of Mycobacterium tuberculosis to pyrazinamide, streptomycin, isoniazid, rifampicin and ethambutol and comparison with the radiometric BACTEC 460 TB method. C Scarparo P Ricardo G Ruggiero P Piccoli, J Clin Microbiol 2004 42 1109 1114 10.1128/JCM.42.3.1109-1114.2004 15004061
17. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide with the nonradiometric BACTEC MGIT 960 system. GE Pfyffer F Palicova S Rusch-Gerdes, J Clin Microbiol 2003 40 1670 1674 10.1128/JCM.40.5.1670-1674.2002
18. Study of initial drug resistance of pyrazinamide in new pulmonary tuberculosis patients before treatment in tuberculosis division by detection of enzyme pyrazinamidase. S Rienthong D Rienthong S Smithikarn S Yamnimnual, Thai J Tuberc Chest Dis 1993 14 85 89
19. Testing of susceptibility of Mycobacterium tuberculosis to pyrazinamide: comparison of Bactec method with pyrazinamidase assay. MA Miller L Thibert F Desjardins SH Siddiqi A Dascal, J Clin Microbiol 1995 33 2468 2470 7494049
20. Comparison of phenotypic and genotypic methods for pyrazinamide susceptibility testing with Mycobacterium tuberculosis. AP Davies OJ Billington TD McHugh DA Mitchison SH Gillespie, J Clin Microbiol 2000 38 3686 3688 11015384
21. Comparison of pyrazinamide drug susceptibility of M. tuberculosis by radiometric Bactec and enzymatic pyrazinamidase assay. Indian. A Krishnamurthy D Almeida C Rodrigues A Mehta, J Med Microbiol 2004 22 166 168
22. Comparative evaluation of Lowenstein-Jensen proportion method, BacT/ALERT 3 D system, and enzymatic pyrazinamidase assay for pyrazinamide susceptibility testing of Mycobacterium tuberculosis. P Singh C Wesley GPS Jadaun SK Malonia R Das P Upadhyay J Faujdar P Sharma P Gupta AK Mishra K Singh DS Chauhan VD Sharma UD Gupta K Venkatesan VM Katoch, J Clin Microbiol 2007 45 76 80 10.1128/JCM.00951-06 17093022
23. Detection of initial drug resistance of pyrazinamide in Thai tuberculosis patients by radiometric method. V Pransucharit C Chuchottaworn, Thai J Tuberc Chest Dis 1995 16 59 65
24. One-tube multiplex PCR method for rapid identification of Mycobacterium tuberculosis. A Chaiprasert T Prammananan N Tingtoy P Na-Ubol S Srimuang K Samerpitak W Rangsipanuratn, Southeast Asian J Trop Med Public Health 2006 37 494 502 17120969
25. Plublic health mycobacteriology. A guide for the level III laboratory. PT Kent GP Kubica, Atlanta: US Department of health and human service 1985
26. Simple pyrazinamidase and urease tests for routine identification of mycobacteria. LG Wayne, Am Rev Respir Dis 1974 109 147 151 4203284
27. Comparative evaluation of polymerase chain reaction and restriction enzyme analysis: two amplified targets, hsp65 and rpoB for identification of cultured mycobacteria. W Cheunoy T Prammananan A Chaiprasert S Foongladda, Diagn Microbiol Infect Dis 2005 51 165 171 10.1016/j.diagmicrobio.2004.09.006 15766601 (Pubitemid 40568759)
28. Molecular characterization of pncA gene mutations in Mycobacterium tuberculosis clinical isolates from China. L Hou D Osei-Hyiaman Z Zhang B Wang A Yang K Kano, Epidemiol Infect 2000 124 227 232 10.1017/S0950268899003635 10813147
29. Genetic and phenotypic characterization of drug-resistant Mycobacterium tuberculosis isolates in Hong Kong. RC Chan M Hui EW Chan TK Au ML Chin CK Yip CK AuYeang CY Yeung KM Kam PC Yip AF Cheng, J Antimicrob Chemother 2007 59 866 873 10.1093/jac/dkm054 17360809
30. Characterization of new mutations in Pyrazinamide-resistant strains of Mycobacterium tuberculosis and identification of conserved regions important for the catalytic activity of the pyrazinamidase PncA. N Lemaitre W Sougakoff C Truffot-Pernot V Jarlier, Antimicrob Agents Chemother 1999 43 1761 1763 10390238
31. Study of the structure-activity relationships for the pyrazinamidase (PncA) from Mycobacterium tuberculosis. N Lemaitre I Callebaut F Frenois V Jarlier W Sougakoff, Biochem J 2001 353 453 458 10.1042/0264-6021:3530453 11171040
32. Crystal structure and mechanism of catalysis of a pyrazinamidase from Pyrococcus horikoshii. X Du W Wang R Kim H Yakota H Nguyen SH Kim, Biochemistry 2001 40 14166 14172 10.1021/bi0115479 11714269
33. Mutations associated with pyrazinamide resistance in pncA of Mycobacterium tuberculosis complex organisms. S Sreevatsan X Pan Y Zhang BN Kreiswirth JM Musser, Antimicrob Agents Chemother 1997 41 636 640 9056006
34. Mutation in pncA is a major mechanism of pyrazinamide resistance in Mycobacterium tuberculosis. K Hirano M Takahashi Y Kazumi Y Fukasawa C Abe, Tuber Lung Dis 1997 78 117 122 10.1016/S0962-8479(98)80004-X 9692180
35. Phenotypic characterization of pncA mutants of Mycobacterium tuberculosis. GP Morlock JT Crawford ER Butler SE Brim D Sikes GH Mazurek CL Woodley RC Cooksey, Antimicrob Agents Chemother 2000 44 2291 2295 10.1128/AAC.44.9.2291-2295.2000 10952570
36. Characterization of pncA mutations pyrazinamide- resistant Mycobacterium tuberculosis in Korea. KW Lee JM Lee KS Jung, J Korean Med Sci 2001 16 537 543 11641519
37. Characterization of pncA mutations in pyrazinamide-resistance Mycobacterium tuberculosis. A Scorpio P Lindholm-Levy L Heifets R Gilman S Siddiqi M Cynamon Y Zhang, Antimicrob Agents Chemother 1997 41 540 543 9055989 (Pubitemid 27098400)